[144] Supernus Pharmaceuticals, Inc. SEC Filing
Supernus Pharmaceuticals (SUPN) Form 144 notice reports an intended sale of 24,150 common shares through Morgan Stanley Smith Barney with an aggregate market value of $1,088,440.50, based on approximately 56,073,088 shares outstanding. The filing lists the approximate sale date as 08/28/2025.
The securities were acquired and are being sold on 08/28/2025 following the exercise of stock options, with payment in cash to the issuer. The filing also discloses multiple recent Rule 10b5-1 sales by Jack A. Khattar in August 2025 totaling sizable share amounts and gross proceeds across several dates, indicating ongoing disposition of shares by this insider.
Supernus Pharmaceuticals (SUPN) - una comunicazione Form 144 segnala l'intenzione di vendere 24.150 azioni ordinarie tramite Morgan Stanley Smith Barney per un valore complessivo di mercato di $1.088.440,50, su un totale di circa 56.073.088 azioni in circolazione. La data indicativa della vendita 猫 il 28/08/2025.
Le titoli sono stati acquistati e saranno venduti il 28/08/2025 a seguito dell'esercizio di stock option, con pagamento in contanti all'emittente. La comunicazione segnala inoltre pi霉 vendite recenti ai sensi della Rule 10b5-1 effettuate da Jack A. Khattar nell'agosto 2025, per importi significativi e proventi lordi distribuiti su diverse date, indicando una continua cessione di azioni da parte di questo insider.
Supernus Pharmaceuticals (SUPN) - un aviso Form 144 informa de la intenci贸n de vender 24.150 acciones comunes a trav茅s de Morgan Stanley Smith Barney por un valor de mercado agregado de $1.088.440,50, sobre aproximadamente 56.073.088 acciones en circulaci贸n. La fecha aproximada de la venta figura como el 28/08/2025.
Los valores fueron adquiridos y se vender谩n el 28/08/2025 tras el ejercicio de opciones sobre acciones, con pago en efectivo al emisor. La presentaci贸n tambi茅n revela m煤ltiples ventas recientes bajo la Rule 10b5-1 realizadas por Jack A. Khattar en agosto de 2025, por montos importantes y con ingresos brutos en varias fechas, lo que indica una disposici贸n continua de acciones por parte de este insider.
Supernus Pharmaceuticals (SUPN)鞚� Form 144 瓿奠嫓電� Morgan Stanley Smith Barney毳� 韱淀暣 齑� 鞁滌灔 臧�旃� $1,088,440.50鞐� 頃措嫻頃橂姅 24,150 氤错喌欤茧ゼ 毵る弰頃� 鞓堨爼鞛勳潉 氤搓碃頄堨姷雼堧嫟. 氚滍枆欤检嫕靾橂姅 鞎� 56,073,088欤检澊氅�, 鞓堨爼 毵り皝鞚检潃 2025-08-28搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟.
頃措嫻 歃濌秾鞚� 2025-08-28鞐� 鞀ろ啞鞓奠厴 頄夓偓鞐� 霐半澕 旆摑霅橃棃瓿�, 氚滍枆靷棎 順勱笀鞙茧 雽�旮堨澊 歆�旮夒悩電� 氚╈嫕鞙茧 毵る弰霅� 鞓堨爼鞛呺媹雼�. 鞝滌稖靹滊電� 霕愴暅 Jack A. Khattar臧� 2025雲� 8鞗旍棎 Rule 10b5-1鞐� 霐半ジ 雼れ垬鞚� 斓滉芳 毵る弰毳� 鞁れ嫓頃� 鞐煬 雮犾鞐� 瓯胳硱 靸侂嫻頃� 欤检嫕靾橃檧 齑濎垬鞚奠潉 旮半頃� 靷嫟鞚� 瓿店皽頃橁碃 鞛堨溂氅�, 鞚措姅 頃措嫻 雮措秬鞛愳潣 歆�靻嶌爜鞚� 欤检嫕 觳橂秳鞚� 鞁滌偓頃╇媹雼�.
Supernus Pharmaceuticals (SUPN) - un avis Form 144 signale l'intention de vendre 24 150 actions ordinaires via Morgan Stanley Smith Barney pour une valeur marchande totale de 1 088 440,50 $, sur environ 56 073 088 actions en circulation. La date approximative de la vente est le 28/08/2025.
Les titres ont 茅t茅 acquis et seront vendus le 28/08/2025 脿 la suite de l'exercice d'options sur actions, avec paiement en esp猫ces 脿 l'茅metteur. Le d茅p么t r茅v猫le 茅galement plusieurs ventes r茅centes selon la Rule 10b5-1 effectu茅es par Jack A. Khattar en ao没t 2025, pour des montants importants et des produits bruts r茅partis sur plusieurs dates, ce qui indique une cession continue d'actions par cet initi茅.
Supernus Pharmaceuticals (SUPN) - Eine Form-144-Mitteilung meldet die geplante Ver盲u脽erung von 24.150 Stammaktien 眉ber Morgan Stanley Smith Barney mit einem Gesamtmarktwert von $1.088.440,50, bei rund 56.073.088 ausstehenden Aktien. Das ungef盲hre Verkaufsdatum ist der 28.08.2025.
Die Wertpapiere wurden erworben und werden am 28.08.2025 nach Aus眉bung von Aktienoptionen verkauft, die Zahlung erfolgt bar an den Emittenten. Die Einreichung offenbart au脽erdem mehrere k眉rzliche Rule-10b5-1-Verk盲ufe von Jack A. Khattar im August 2025 mit betr盲chtlichen St眉ckzahlen und Bruttoerl枚sen an verschiedenen Terminen, was auf eine fortgesetzte Ver盲u脽erung von Aktien durch diesen Insider hinweist.
- Transaction executed through an established broker (Morgan Stanley Smith Barney LLC), supporting orderly processing of the sale
- Seller used or disclosed Rule 10b5-1 sales in prior transactions, indicating reliance on preestablished trading plans for some disposals
- Securities were acquired by exercise of stock options and paid in cash on the acquisition date, showing a clear acquisition-to-sale link
- Concentrated insider selling in August 2025 with multiple large 10b5-1 transactions (e.g., 63,500 and 38,500 shares) which could increase supply pressure
- Large gross proceeds reported from recent sales (several transactions totaling millions of dollars), which may attract investor attention to insider dispositions
- Form 144 lacks certain timing details about plan adoption dates or explicit Form 4 references within the provided content, limiting completeness of oversight information
Insights
TL;DR: Routine insider sale following option exercise; size is modest relative to shares outstanding but notable in dollar terms.
The filing documents a planned disposal of 24,150 shares valued at approximately $1.09 million, executed through a major broker and tied to an option exercise on the same date. For a company with ~56.1 million shares outstanding, this single transaction represents roughly 0.043% of the share count, suggesting limited immediate dilution or market impact. However, the presence of several contemporaneous 10b5-1 sales by the same insider in August 2025 increases total insider supply to the market over a short period, which could put localized selling pressure depending on trading liquidity and market interest.
TL;DR: Compliance disclosure appears standard, but concentrated insider sales warrant attention to plan timing and disclosure completeness.
The Form 144 indicates the seller represents no undisclosed material information and records multiple 10b5-1 transactions in August 2025 by Jack A. Khattar, including trades of 38,500; 38,000; 63,500; 10,650; 1,000; and 1,500 shares on various August dates with material gross proceeds reported. While use of a broker and 10b5-1 language aligns with standard compliance practice, the concentration and magnitude of sales within the month elevate monitoring needs for adherence to trading plan dates and insider reporting timelines. From a governance perspective, completeness of corresponding Form 4 filings and consistency with stated plan adoption dates (not provided here) are key compliance checkpoints.
Supernus Pharmaceuticals (SUPN) - una comunicazione Form 144 segnala l'intenzione di vendere 24.150 azioni ordinarie tramite Morgan Stanley Smith Barney per un valore complessivo di mercato di $1.088.440,50, su un totale di circa 56.073.088 azioni in circolazione. La data indicativa della vendita 猫 il 28/08/2025.
Le titoli sono stati acquistati e saranno venduti il 28/08/2025 a seguito dell'esercizio di stock option, con pagamento in contanti all'emittente. La comunicazione segnala inoltre pi霉 vendite recenti ai sensi della Rule 10b5-1 effettuate da Jack A. Khattar nell'agosto 2025, per importi significativi e proventi lordi distribuiti su diverse date, indicando una continua cessione di azioni da parte di questo insider.
Supernus Pharmaceuticals (SUPN) - un aviso Form 144 informa de la intenci贸n de vender 24.150 acciones comunes a trav茅s de Morgan Stanley Smith Barney por un valor de mercado agregado de $1.088.440,50, sobre aproximadamente 56.073.088 acciones en circulaci贸n. La fecha aproximada de la venta figura como el 28/08/2025.
Los valores fueron adquiridos y se vender谩n el 28/08/2025 tras el ejercicio de opciones sobre acciones, con pago en efectivo al emisor. La presentaci贸n tambi茅n revela m煤ltiples ventas recientes bajo la Rule 10b5-1 realizadas por Jack A. Khattar en agosto de 2025, por montos importantes y con ingresos brutos en varias fechas, lo que indica una disposici贸n continua de acciones por parte de este insider.
Supernus Pharmaceuticals (SUPN)鞚� Form 144 瓿奠嫓電� Morgan Stanley Smith Barney毳� 韱淀暣 齑� 鞁滌灔 臧�旃� $1,088,440.50鞐� 頃措嫻頃橂姅 24,150 氤错喌欤茧ゼ 毵る弰頃� 鞓堨爼鞛勳潉 氤搓碃頄堨姷雼堧嫟. 氚滍枆欤检嫕靾橂姅 鞎� 56,073,088欤检澊氅�, 鞓堨爼 毵り皝鞚检潃 2025-08-28搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟.
頃措嫻 歃濌秾鞚� 2025-08-28鞐� 鞀ろ啞鞓奠厴 頄夓偓鞐� 霐半澕 旆摑霅橃棃瓿�, 氚滍枆靷棎 順勱笀鞙茧 雽�旮堨澊 歆�旮夒悩電� 氚╈嫕鞙茧 毵る弰霅� 鞓堨爼鞛呺媹雼�. 鞝滌稖靹滊電� 霕愴暅 Jack A. Khattar臧� 2025雲� 8鞗旍棎 Rule 10b5-1鞐� 霐半ジ 雼れ垬鞚� 斓滉芳 毵る弰毳� 鞁れ嫓頃� 鞐煬 雮犾鞐� 瓯胳硱 靸侂嫻頃� 欤检嫕靾橃檧 齑濎垬鞚奠潉 旮半頃� 靷嫟鞚� 瓿店皽頃橁碃 鞛堨溂氅�, 鞚措姅 頃措嫻 雮措秬鞛愳潣 歆�靻嶌爜鞚� 欤检嫕 觳橂秳鞚� 鞁滌偓頃╇媹雼�.
Supernus Pharmaceuticals (SUPN) - un avis Form 144 signale l'intention de vendre 24 150 actions ordinaires via Morgan Stanley Smith Barney pour une valeur marchande totale de 1 088 440,50 $, sur environ 56 073 088 actions en circulation. La date approximative de la vente est le 28/08/2025.
Les titres ont 茅t茅 acquis et seront vendus le 28/08/2025 脿 la suite de l'exercice d'options sur actions, avec paiement en esp猫ces 脿 l'茅metteur. Le d茅p么t r茅v猫le 茅galement plusieurs ventes r茅centes selon la Rule 10b5-1 effectu茅es par Jack A. Khattar en ao没t 2025, pour des montants importants et des produits bruts r茅partis sur plusieurs dates, ce qui indique une cession continue d'actions par cet initi茅.
Supernus Pharmaceuticals (SUPN) - Eine Form-144-Mitteilung meldet die geplante Ver盲u脽erung von 24.150 Stammaktien 眉ber Morgan Stanley Smith Barney mit einem Gesamtmarktwert von $1.088.440,50, bei rund 56.073.088 ausstehenden Aktien. Das ungef盲hre Verkaufsdatum ist der 28.08.2025.
Die Wertpapiere wurden erworben und werden am 28.08.2025 nach Aus眉bung von Aktienoptionen verkauft, die Zahlung erfolgt bar an den Emittenten. Die Einreichung offenbart au脽erdem mehrere k眉rzliche Rule-10b5-1-Verk盲ufe von Jack A. Khattar im August 2025 mit betr盲chtlichen St眉ckzahlen und Bruttoerl枚sen an verschiedenen Terminen, was auf eine fortgesetzte Ver盲u脽erung von Aktien durch diesen Insider hinweist.
FAQ
What shares and value does the SUPN Form 144 report for sale?
When is the approximate sale date listed in the filing?
How were the securities acquired prior to this sale?
Who executed the sale and through which broker?
Has the seller made recent sales in the past three months?
